Long-term benefits of early initiation of ivacaftor (IVA) in people with cystic fibrosis (CF): interim results from an ongoing registry-based study
M. Higgins (London, United Kingdom), N. Volkova (Boston, United States), T. Farietta (Boston, United States), M. Liu (Boston, United States), R. Wu (Bethesda , United States), A. Elbert (Bethesda , United States), S. Charman (London, United Kingdom), A. Lee (London, United Kingdom), S. Cunningham (Edinburgh, United Kingdom)
Source: International Congress 2022 – Monitoring the effect of therapy with CFTR modulators
Session: Monitoring the effect of therapy with CFTR modulators
Session type: Oral Presentation
Number: 1616
   
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Higgins (London, United Kingdom), N. Volkova (Boston, United States), T. Farietta (Boston, United States), M. Liu (Boston, United States), R. Wu (Bethesda , United States), A. Elbert (Bethesda , United States), S. Charman (London, United Kingdom), A. Lee (London, United Kingdom), S. Cunningham (Edinburgh, United Kingdom). Long-term benefits of early initiation of ivacaftor (IVA) in people with cystic fibrosis (CF): interim results from an ongoing registry-based study. 1616
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|